Biopharmaceutical company Erasca announced on Monday that its experimental RAS-targeting pill, ERAS-0015, demonstrated significant tumor reduction in early-stage clinical trials for advanced pancreatic and non-small cell lung cancer.
According to the company, the drug shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced non-small cell lung cancer. Erasca described these preliminary results as exceeding expectations.
The data were collected from studies conducted in the United States and China, though the company emphasized that the findings remain preliminary.
Comparative Efficacy and Tolerability
Erasca reported that the clinical benefit and tolerability profile of ERAS-0015 compared favorably to daraxonrasib, a similar RAS-targeting therapy developed by Revolution Medicines. Recent data from Revolution Medicines showed that daraxonrasib doubled overall survival in patients with advanced pancreatic cancer.
CEO’s Perspective on Trial Results
“I’m excited about both datasets, but I think lung is more definitive at this point. The pancreatic results are maturing, but are very, very promising. All options are on the table.”
— Jonathan Lim, CEO of Erasca
Lim’s remarks highlight the company’s optimism while acknowledging that further maturation of the pancreatic cancer data is needed. Erasca has not ruled out potential next steps, including further development or partnerships.
Related articles
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Ballmaxxing: The Dangerous Testicle Enhancement Trend You Need to Know About
Experts say that “Ballmaxxing” may lead to permanent damage. Image Credit: Heathline/Paloma Rincon Studio/GettyImages Ballmaxxing is the latest social...
Study Links High Air Pollution to Increased Post-Surgical Complications on Utah’s Wasatch Front
New research on Utah’s Wasatch Front—which occasionally experiences the worst air quality in the nation—has found an association between high air poll...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...
CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up u...